NASDAQ · ABBV
Healthcare · Drug Manufacturers - General
$265.21
Up+$0.09 (+0.03%)
Updated Sep 23, 2026, 11:27 PM
SID Score
7.0/10
Composite research score
Smart Money
53/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ABBV closed at $265.21 after 20 trading sessions, down 0.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $263.10 | $266.82 | $262.145 | $265.21 | 2.77M |
| Sep 21, 2026 | $263.07 | $266.5998 | $261.23 | $264.48 | 3.44M |
| Sep 18, 2026 | $263.29 | $266.34 | $262.44 | $263.96 | 8.18M |
| Sep 17, 2026 | $262.61 | $264.62 | $260.88 | $264.02 | 3.51M |
| Sep 16, 2026 | $261.99 | $264.00 | $260.975 | $262.51 | 3.12M |
| Sep 15, 2026 | $260.00 | $264.81 | $257.795 | $263.04 | 5.12M |
| Sep 14, 2026 | $261.67 | $264.6499 | $260.1001 | $261.77 | 4.51M |
| Sep 11, 2026 | $253.92 | $259.61 | $253.92 | $257.12 | 4.31M |
| Sep 10, 2026 | $251.23 | $255.31 | $249.735 | $255.00 | 4.4M |
| Sep 9, 2026 | $247.73 | $251.18 | $246.7701 | $250.91 | 3.87M |
| Sep 8, 2026 | $251.84 | $254.615 | $248.41 | $248.78 | 5.57M |
| Sep 4, 2026 | $257.96 | $258.91 | $255.58 | $256.46 | 4.73M |
| Sep 3, 2026 | $264.00 | $264.25 | $257.14 | $260.21 | 2.88M |
| Sep 2, 2026 | $262.70 | $262.97 | $257.70 | $261.72 | 4.23M |
| Sep 1, 2026 | $260.99 | $262.265 | $257.79 | $259.99 | 3.87M |
| Aug 31, 2026 | $254.17 | $258.24 | $252.33 | $256.42 | 4.32M |
| Aug 28, 2026 | $258.67 | $259.00 | $255.0797 | $255.48 | 3.22M |
| Aug 27, 2026 | $260.81 | $262.4977 | $257.25 | $258.15 | 4.76M |
| Aug 26, 2026 | $264.60 | $265.00 | $260.31 | $262.90 | 3.31M |
| Aug 25, 2026 | $264.50 | $266.905 | $263.025 | $265.79 | 3.67M |
The latest Smart Investors Daily articles mentioning ABBV.
ABBV research
Company profile and research snapshot.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Buy | — |
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 17, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Aug 11, 2026 | BNP Paribas | Neutral | — |
Generated Sep 23, 2026, 9:00 PM
AbbVie shares are essentially flat with a minimal $0.09 gain, reflecting investor hesitation despite positive regulatory news. The company secured European Commission approval for Rinvoq in pediatric arthritis, a meaningful expansion of the drug's market reach, though the modest stock reaction suggests the market had largely priced in this development.
Bottom line: AbbVie's EU approval for Rinvoq in pediatric arthritis is a positive development that extends the drug's market reach, yet today's flat price action reflects realistic market expectations about the incremental nature of this indication. Investors should monitor whether the company can leverage this pediatric approval into meaningful revenue growth while keeping watch on competitive dynamics in the immunology space and the company's overall dividend sustainability.
Yahoo · Sep 23, 2026
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]
SeekingAlpha · Sep 23, 2026
AbbVie is rated a "Sell" with a $191 target, implying 27.7% downside from the current $264 price. Click here to read more about the ABBV stock.
Benzinga · Sep 23, 2026
A September filing shows that Representative Pete Sessions reported a sale in Apple (NASDAQ:AAPL), valued between $100,001 and $250,000. The transaction date is listed as September 22, 2026, with the report published on
Yahoo · Sep 23, 2026
AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. Allergan Aesthetics launched AA Signature SKIN360 in the U.S., offering a multimodal digital platform for medical aesthetics consultations. AbbVie entered AI-focused collaborations with Iambic and the AISB Bind project to use advanced models in drug discovery and molecular binding prediction. The RINVOQ pediatric extension, AA Signature SKIN360...
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. shares traded at $265.32, reflecting a single-day decline of 1.32% per SID market data. Despite the near-term pullback, the stock has demonstrated sustained momentum across longer horizons, posting a 1.01% gain over the trailing one-month period, a 14.99% advance over three months, and a 16.28% increase year-over-year. Technically, ABBV trades above both key moving averages, with its 50-day moving average at $255.68 and its 200-day moving average at $230.11, indicating a constructive trend structure according to SID market data. The 14-day RSI stands at 61.5, positioning the stock in neutral-to-moderately bullish territory without yet reaching overbought levels. Average daily volume registers at approximately 6.4 million shares. ABBV's beta of 0.334 reflects significantly lower volatility relative to the broader market, consistent with its classification within the defensive Healthcare sector. The company's market capitalization stands at approximately $410 billion.
AbbVie Inc. presents a complex valuation profile driven by significant intangible asset amortization and acquisition-related charges. The company's trailing price-to-earnings ratio stands at 97.75, a figure substantially elevated relative to Healthcare sector peers, per SID market data. However, the PEG ratio of 1.25 suggests a more moderate valuation when adjusted for anticipated earnings growth, indicating the high P/E partly reflects expected recovery in forward earnings. Notably, the price-to-book ratio is negative at -126.33 according to SEC filings, a consequence of accumulated goodwill impairments and debt-financed acquisitions, particularly the $63 billion Allergan deal, which resulted in negative book equity. The dividend yield of 2.87% remains an attractive feature for income-oriented investors, supported by AbbVie's track record as a Dividend Aristocrat. The valuation disconnect between the elevated P/E and the reasonable PEG ratio underscores the importance of analyzing forward earnings trajectories rather than trailing metrics alone.
AbbVie Inc. registers a composite smart money score of 53 out of 100, reflecting a neutral overall signal per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained buying interest among large fund managers as reported in 13F institutional filings. The insider trading component scores 18 out of 25, bolstered by two insider purchases and zero insider sales recorded over the past 90 days according to SEC Form 4 filings. This exclusively buy-side insider activity suggests confidence among company executives at current price levels. Conversely, the dark pool activity score of 9.6 out of 25 points to below-average off-exchange accumulation patterns. Congressional trading activity is minimal, registering just 0.8 out of 25. The divergence between strong institutional and insider signals and weaker dark pool and congressional indicators produces the overall neutral composite reading. The absence of any insider selling during a period of meaningful stock appreciation is a notable data point worth monitoring.
AbbVie Inc.'s recent earnings results show a mixed trajectory according to company earnings reports. In the most recent completed quarter reported on February 4, 2026, ABBV delivered earnings per share of $2.71, exceeding the consensus estimate of $2.66 by $0.05. The subsequent quarter reported April 29 showed EPS of $2.65 against estimates of $2.66, a near-inline miss of just $0.01. However, the quarter reported July 31 reflected a more pronounced shortfall, with actual EPS of $3.65 falling below the $3.77 estimate by $0.12. An upcoming quarterly report carries analyst estimates of $3.01 per share. The sequential earnings pattern reveals a deceleration from outperformance to underperformance relative to consensus expectations. This trajectory will be closely tracked by market participants assessing whether AbbVie's immunology and oncology franchises, including Skyrizi and Rinvoq, are offsetting the ongoing Humira biosimilar erosion at sufficient pace.
Wall Street consensus on AbbVie Inc. leans constructive, with the majority of recent analyst actions reflecting positive or maintained bullish stances per Wall Street analyst reports. HSBC reiterated a Buy rating on September 10, 2026, while Piper Sandler maintained an Overweight rating on August 20 and Wells Fargo similarly held its Overweight stance on August 17. The most notable change came from Wolfe Research, which upgraded ABBV to Outperform from Peer Perform on August 13, representing the sole directional shift among recent coverage updates. BNP Paribas maintained a Neutral rating on August 11, representing the lone non-bullish stance in the current analyst sample. Per SID consensus data, four of the five most recent analyst actions carry bullish or outperform-equivalent ratings, suggesting broad institutional confidence in AbbVie's growth trajectory. The Wolfe Research upgrade is particularly significant as it signals a new convert to the bullish thesis amid the company's ongoing portfolio transition beyond Humira.
The latest Smart Investors Daily articles mentioning ABBV.
